Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 33, Issue 11, 2006, Pages 2153-2161

  Kawai, Shinichi ^a   Hashimoto, Hiroshi ^b   Kondo, Hirobumi ^c   Murayama, Takashi ^d   Kiuchi, Takahiro ^e   Abe, Toru ^f  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Center of Rheumatology and Collagen Diseases   (Japan)

^e UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Mizoribine; Randomized controlled trial; Rheumatoid arthritis; Tacrolimus

Indexed keywords

ACTARIT; AURANOFIN; AUROTHIOMALATE; BETA 2 MICROGLOBULIN; BUCILLAMINE; CEFTRIAXONE; CLARITHROMYCIN; CREATININE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; LOBENZARIT; MAGNESIUM; MEROPENEM; METHOTREXATE; MIZORIBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; POTASSIUM; SALAZOSULFAPYRIDINE; TRIACYLGLYCEROL; TSUKUBAENOLIDE; URIC ACID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CELLULITIS; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECZEMA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; JAPAN; LIMB DISEASE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MODIFIED HEALTH ASSESSMENT QUESTIONNAIRE; MUSCULOSKELETAL DISEASE; PAIN ASSESSMENT; PERICARDITIS; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SKIN DISEASE; SKIN PRURITUS; SORE THROAT; STOMACH DYSPHORIA; STOMACH PAIN; STOMATITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION; VISUAL DISORDER;

ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RIBONUCLEOSIDES; TACROLIMUS; TREATMENT OUTCOME;

EID: 33750973069     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Lerut J, Mathys J, Lemaire J, et al. Tacrolimus monotherapy in 100 adult liver transplant recipients: one year results of a prospective, randomized, blinded, placebo-controlled, single centre study [abstract]. Transplantation 2004;78:173.
2. Artz MA, Boots JMM, Ligtenberg G, et al. Conversion from cyclosporine to tacrolimus improves qualily-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004;4:937-45.
3. Kramer BK, Krüger B, Mack M, et al. Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens. Transplant Proc 2005;37:1789-91.
4. Pollock-Bar Ziv SM, Dipchand AI, McCrindle BW, Nalli N, West LJ. Allograft rejection in pediatric heart transplant recipients on tacrolimus or cyclosporine primary immunosuppression: results of a randomized trial at mean 25 month follow-up. Am J Transplant 2004;4 Suppl 8:177.
5. Sarahrudi K, Estenne M, Corris P, et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg 2004;127:1126-32.
6. Bechstein WO. Efficacy and safety of tacrolimus compared with cyelosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial. Transplantation 2004;77:1221-8.
7. Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001;44 Suppl:S65-72.
8. Moeremans K, Annemans L. Economic evaluation of tacrolimus ointment versus current care in moderate to severe atopic dermatitis. Value Health 2003;6:784-5.
9. Konishi T, Yoshiyama Y, Takamori M, Yagi K, Mukai E, Saida T: Japanese FK MG Study Group. Clinical study of FK506 in patients with myasthenia gravis. Muscle Nerve 2003;:28:570-4.
10. Kawaguchi T, Yoshiyama Y, Nemoto Y, Munakata S, Fukutake T, Hattori T. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin 2004;20:1269-73.
11. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot 1987;40:1256-65.
12. Kelly PA, Burckart GJ, Venkataramanan R. Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm 1995;52:1569-71.
13. Kondo H, Abe T, Hashimoto H, et al. Efficacy and safety of tacrolimus (FK) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J Rheumatol 2004;31:243-51.
14. Yocum DE, Furst DE, Kaine JL, et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum 2003;48:3328-37.
15. Furst DE, Saag K, Fleischmann MR, et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum 2002;46:2020-8.
16. Ishikawa H. Mizoribine and mycophenolate mofetil. Curr Med Chem 1999;6:575-97.
17. Takei S. Mizoribine in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. Pediatr Int 2002;44:205-9.
18. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
19. Pincus T, Summey JA, Sopaci SA, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;:26:1346-53.
20. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
21. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
22. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
23. Prevoo ML, van Gestel AM, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996;35:1101-5.
24. Methotrexate prescribing information. Cranbury, NJ, USA: Stada Pharmaceutical, Inc. Revised 10/2003 Rhumatrex®.
25. Dadoniene J, Uhlig T, Stropuviene S, Venalis A, Boonen A, Kvien TK. Disease activity and health status in rheumatoid arthritis: a case-control comparison between Norway and Lithuania. Ann Rheum Dis 2003;62:231-5.
26. Wilke WS. Should methotrexate be a first-line treatment for rheumatoid arthritis? Cleve Clin J Med 1999;66:207-8.
27. Bottiger Y, Brattström C, Tyden G, Sawe J, Groth CG. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol 1999;48:445-8.
28. Kawai S, Yamamoto K. Treatment of rheumatoid arthritis in elderly patients. Rheumatology Oxford 2006;45:441-4.